A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
Premier submitted comments to the Food and Drug Administration (FDA) regarding its discussion paper on using artificial intelligence (AI) and Machine Learning (ML) in the development of drug and biological products.
Premier supports the development of the FDA's discussion paper as a positive step towards recognizing the ways in which technology can be leveraged to reduce costs, improve data quality and access, expedite processes and advance health equity. Specifically, Premier applauds the FDA’s efforts to incorporate emerging technologies into drug development and provide clarity for clinical trial innovators. In its comments, Premier recommends that the FDA consider: